‹ Madrigal Pharmaceuticals
Ch 5 · The Story Behind the Numbers
Chapter 5 · Behind the Numbers
The numbers, in the company's own words.
Every filing has a section where management explains what just happened — and why. Here's Madrigal's.
↓ scroll to read
✦ The bottom line
Anyone can read the revenue line. The story — why it's ramping, where profit is, and what threatens it — is the part Madrigal writes itself. Here are the threads that matter.
↓ the brief below
✦ Five threads from Madrigal's filings
1
One drug is the whole company.
Rezdiffra is Madrigal's only approved product. Nearly all value rides on it — its launch, its pricing, and its defense. That's the strength (focus) and the risk (concentration) at once.
2
The launch is still early — and huge.
Revenue more than doubled year-over-year and is approaching a $1B+ run-rate, but it's only scratched the surface of the millions of MASH patients. The patient backlog for a first-ever treatment is the fuel.
3
Profit is close.
The operating loss shrank to $300M on $958M of revenue and keeps narrowing. With pharma's high margins, continued growth should flip Madrigal to profitability — a milestone most spicy names are nowhere near.
4
The plan is to widen the label.
Madrigal is pursuing approval to treat a broader MASH population (including more advanced disease). A wider label means a bigger addressable market — and a deeper moat before rivals arrive.
5
Competition is the cloud on the horizon.
MASH is a massive market, which guarantees rivals — including the GLP-1 obesity drugs — will target it. Madrigal's head start is real, but the filing is candid that approval, payors, and competition all shape Rezdiffra's future.
Source · 10-K · MD&A + Business · FY2025 · Filed Feb 19, 2026
●
Read the whole story
Five threads: one drug is everything, the launch is early and huge, profit is close, the label may widen, and competition is coming.
You just finished
Chapter 5 · BEHIND THE NUMBERS
The Story Behind the Numbers
you now read: reading the MD&A
Up next